No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BBIO BridgeBio Pharma
- 24.740
- -0.210-0.84%
Close Apr 19 16:00 ET
- 24.880
- +0.140+0.57%
Post 17:34 ET
4.56BMarket Cap-6263P/E (TTM)
25.355High24.270Low2.30MVolume24.880Open24.950Pre Close56.90MTurnover1.94%Turnover RatioLossP/E (Static)184.45MShares44.32052wk High-3.37P/B2.93BFloat Cap12.75052wk Low--Dividend TTM118.57MShs Float73.500Historical High--Div YieldTTM4.35%Amplitude4.980Historical Low24.751Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Affirmed for BridgeBio Pharma on Acoramidis' Positive ATTR-CM Trial Outcomes
Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 Trial Of Acoramidis In ATTR-CM
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression- T
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent With Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented results from the exploratory CMR imaging substudy of ATTRibute-CM, its Phase 3 trial of acoramidis in ATTR-CM.
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
Comments
ColumnsToday's Morning Movers and Top Ratings: GOOGL, AMD, TSLA, SBUX and More
Morning Movers
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
Gapping up
$Starbucks(SBUX.US$ stock rose 3.7% after the coffee chain cut its annual sales forecast, warning of softer demand in January and a slow recovery in China. However, even more weakness had been expected following disappointing store traffic in November and December.
$Novo-Nordisk A/S(NVO.US$ stock rose 0.5% after the Danish drugmaker forecast another year of double-digit growth due to the populari...
17
ColumnsBiotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$S&P 500 Index(.SPX.US$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
28
1
Update
$BridgeBio Pharma(BBIO.US$ BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg